World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 27 May 2019
Main ID:  ChiCTR1900023410
Date of registration: 2019-05-26
Prospective Registration: Yes
Primary sponsor: Shanghai Tongren Hospital
Public title: The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease
Scientific title: The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease
Date of first enrolment: 2019-06-01
Target sample size: Target condition:40;Difficult condition:20
Recruitment status: Recruiting
Study type:  Diagnostic test
Study design:  Factorial  
Phase:  0
Countries of recruitment
Name: Xiaoping Wang   
Address:  1111 Xianxia Road, Changning District, Shanghai
Telephone: +86 13311986373
Affiliation:  Shanghai Tongren Hospital
Name: Xiangzhen Yuan   
Address:  1111 Xianxia Road, Changning District, Shanghai
Telephone: +86 19916546114
Affiliation:  Shanghai Tongren Hospital
Key inclusion & exclusion criteria
Inclusion criteria: (1) The patients meet the diagnostic criteria of Wilson's disease, including the newly diagnosed patient and the previously diagnosed patient.
(2) The patient with Wilson's disease are beteen 10 years old and 50 years old.
(3) The patients or their guardians shall give informed consent and sign the informed consent.

Exclusion criteria: The patients cannot tolerate magnetic resonance examination or have metal implants in the body, which is not suitable for magnetic resonance examination.

Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Wilson’s disease
Gold Standard:The main clinical diagnostic criteria: 1) liver disease history, liver disease symptoms or extravertebral system symptoms; 2) serum ceruloplasmin was significantly decreased and/or liver copper increased; 3) corneal Kayser-Fleischer ring; 4) positive family history.;Index test:Quantitative susceptibility mapping;
Primary Outcome(s)
magnetic susceptibility;SEN, SPE, ROC;
Secondary Outcome(s)
Copper ion concentration;Iron ion concentration;
Secondary ID(s)
Source(s) of Monetary Support
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 17/04/2019
Lihua Bai
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history